Skip to main content
. 2020 Nov 16;130(12):6739–6753. doi: 10.1172/JCI139681

Figure 6. Effect of estradiol supplementation on response to MVT-602 in women during the healthy follicular phase.

Figure 6

(A and B) Mean (± SEM) change from baseline in serum LH (IU/L) (A) and serum FSH (IU/L) (B) in healthy women receiving a single s.c. bolus of 0.03 nmol/kg MVT-602 (blue), and in women with estradiol supplementation (n = 5 per group) via a 200-μg/d transdermal patch applied from 24 hours before MVT-602 administration at time 0 hours and continued until time 48 hours (red). (C and D) Scatterplot of median (IQR) of maximal rise in serum LH (IU/L) (C) and serum FSH (IU/L) (D) in healthy women receiving a single s.c. bolus of 0.03 nmol/kg MVT-602 (blue), and in women with estradiol supplementation (n = 5 per group) via a 200-μg/d transdermal patch applied from 24 hours before MVT-602 administration at time 0 hours and continued until time 48 hours (red). Groups were compared by Mann-Whitney U test (*P = 0.016, **P = 0.0079).